# A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

> **NCT06227832** · PHASE1 · COMPLETED · sponsor: **Kaken Pharmaceutical** · enrollment: 38 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** KP-001
- **DRUG:** Metformin
- **DRUG:** Midazolam
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT06227832
- **Lead sponsor:** Kaken Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-07-31
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227832, "A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06227832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*